WO2012102511A2 - Ginger extract production method and ginger extract obtained thereby - Google Patents
Ginger extract production method and ginger extract obtained thereby Download PDFInfo
- Publication number
- WO2012102511A2 WO2012102511A2 PCT/KR2012/000437 KR2012000437W WO2012102511A2 WO 2012102511 A2 WO2012102511 A2 WO 2012102511A2 KR 2012000437 W KR2012000437 W KR 2012000437W WO 2012102511 A2 WO2012102511 A2 WO 2012102511A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ginger
- extract
- supercritical
- ginger extract
- extraction
- Prior art date
Links
- 235000020708 ginger extract Nutrition 0.000 title claims abstract description 86
- 229940002508 ginger extract Drugs 0.000 title claims abstract description 85
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 36
- 241000234314 Zingiber Species 0.000 claims abstract description 111
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 109
- 235000008397 ginger Nutrition 0.000 claims abstract description 109
- 238000000194 supercritical-fluid extraction Methods 0.000 claims abstract description 35
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 27
- 238000000605 extraction Methods 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 19
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 239000010649 ginger oil Substances 0.000 claims description 15
- 239000011888 foil Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 3
- 244000241235 Citrullus lanatus Species 0.000 claims 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 53
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 abstract description 20
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 abstract description 18
- 235000002780 gingerol Nutrition 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 235000019640 taste Nutrition 0.000 abstract description 3
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 36
- 230000003078 antioxidant effect Effects 0.000 description 21
- 230000003013 cytotoxicity Effects 0.000 description 16
- 231100000135 cytotoxicity Toxicity 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 241000219122 Cucurbita Species 0.000 description 11
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 11
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 11
- 230000002000 scavenging effect Effects 0.000 description 11
- 235000009852 Cucurbita pepo Nutrition 0.000 description 10
- 230000002292 Radical scavenging effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 210000003630 histaminocyte Anatomy 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 102000016761 Haem oxygenases Human genes 0.000 description 7
- 108050006318 Haem oxygenases Proteins 0.000 description 7
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 5
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- AIULWNKTYPZYAN-SFHVURJKSA-N (10)-Gingerol Chemical compound CCCCCCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 AIULWNKTYPZYAN-SFHVURJKSA-N 0.000 description 3
- AIULWNKTYPZYAN-UHFFFAOYSA-N 810gingerol Natural products CCCCCCCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 AIULWNKTYPZYAN-UHFFFAOYSA-N 0.000 description 3
- -1 ABTS cation Chemical class 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- BCIWKKMTBRYQJU-INIZCTEOSA-N (8)-Gingerol Chemical compound CCCCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 BCIWKKMTBRYQJU-INIZCTEOSA-N 0.000 description 2
- ZEASWHWETFMWCV-UHFFFAOYSA-N 7-O-(2-O-Acetyl-6-O-Methyl-beta-D-glucuronoside)-4',5,7-Trihydroxyflavone Natural products C=1C(O)=C(O)C2=C(O)C(=O)C=C(C3C(CC4=C(O)C=C(O)C=C4O3)OC(=O)C=3C=C(O)C(O)=C(O)C=3)C=C2C=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-UHFFFAOYSA-N 0.000 description 2
- VSDUZFOSJDMAFZ-UHFFFAOYSA-N 8-gingerol Natural products COC(=O)C(N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 102000002268 Hexosaminidases Human genes 0.000 description 2
- 108010000540 Hexosaminidases Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 2
- CQOOYORMTIZYCE-UHFFFAOYSA-N 2,4-diethyl-1,3-benzothiazole Chemical compound C1=CC=C2SC(CC)=NC2=C1CC CQOOYORMTIZYCE-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- 235000012432 gingerbread Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 1
- 229930001895 zingiberene Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Extraction Or Liquid Replacement (AREA)
- Seasonings (AREA)
Abstract
The present invention relates to a supercritical extraction method and to a method for producing ginger extract which has a potent anti-inflammatory effect by using the lees which remain after the extraction and to a ginger extract obtained thereby. More specifically, a method is provided for obtaining an extract with a high gingerol content while not only making it possible to either remove or complement the specific taste and smell of ginger but also affording a high extraction yield in a short time, by subjecting ginger powder to supercritical extraction at a temperature of between 35 and 55°C and a pressure of between 100 and 400 bar at a flow rate of between 1 and 3 mL/min for between 1 and 3 hours, using supercritical carbon dioxide. Also, provided is a method for obtaining a ginger extract having potent anti-inflammatory and anti-allergy activity through the use of ginger lees, by adding 60 to 90% alcohol to the lees which remain after the supercritical extraction, in an amount of between 5 and 15 times (w/v) the weight of the ginger lees, and allowing to stand for between 6 and 36 hours at room temperature.
Description
【명세서】 【Specification】
【발명의 명칭】 [Name of invention]
생강 추출물 제조방법 및 이에 따른 생강 추출물 【기술분야】 Preparation method of ginger extract and ginger extract according thereto
본 발명은 초임계 추출방법 및 추출후 남은 박을 이용하여 항염 및 항알러지 효과가 높은 생강 추출물을 제조하는 방법 및 이에 따른 생강 추출물에 대한 것이다. 【배경기술】 The present invention relates to a method for producing a ginger extract with high anti-inflammatory and anti-allergic effect using the supercritical extraction method and the remaining gourd after extraction, and the ginger extract accordingly. Background Art
생강은 우리나라뿐 아니라 세계적으로 널리 이용되고 있는 향신료의 하나이며 식품의 관능성을 향상시키기 위해 첨가하는 조미성분의 하나로 널리 이용되고 있다. 또한, 생강은 인체에 유익한 여러 가지 성분이 함유되어 있어 차 (tea)나 약재로 널리 쓰여 왔다. Ginger is one of spices widely used not only in Korea but also in the world and is widely used as one of the seasoning ingredients added to improve the sensory properties of food. In addition, ginger contains a variety of ingredients beneficial to the human body has been widely used as tea (tea) or medicine.
생강은 생강과에 속하는 아열대 및 열대성 다년생 식물로서 근경을 주로 이용하여， 특유의 향과 매운 맛이 있어서 오랫동안 향신료로 사용되어 왔다, 한방에서는 생강의 뿌리줄기 말린 것을 건강이라는 약재로 쓰고 있다. 건강은 소화불량 구토설사에 효과가 있고, 혈액순환을 촉진하며 항염증과 진통효과가 있다. Ginger is a subtropical and tropical perennial plant belonging to the family Ginger, and has been used as a spice for a long time because of its unique aroma and spicy taste. In oriental medicine, the root stem of ginger is used as a medicine for health. Health is effective in indigestion and vomiting diarrhea, promotes blood circulation, anti-inflammatory and analgesic effect.
생강의 4분의 3정도는 수분이며 전체 고형분의 40~60¾>는 전분이 차지하고 있다. 정유성분으로는 진기베를 (zingiberol), 진기베렌 About three quarters of ginger is water, and 40 to 60¾ of total solids is made up of starch. Essential oils include zingiberol and gingiberen
(zingiberene) 등이 함유되어 있으며 , 특이 성분으로는 6—진저롤 (gingerol， 0.1-0.3%), 8-진저를 (gingerol), 10-진저를 (gingerol ) , 진저론 (zingerone) , 6-쇼가을 (6ᅳ shogaol , 0.04%), 감마-아미노부티르산 (ga誦 a— aminobutyric ' acid) 등이 있다. 초임계 유체에 의한 천연물의 추출은 많은 관심의 대상이 되고 있다. 초임계 유체를 이용하는 추출 및 분리기술은 임계점 부근 또는 임계점을 초월하는 영역에서 초임계 유체의 특이한 물리적 특성을 이용하여 흔합성분 중 특정성분을 선택적으로 추출하는 분리기술의 하나이다. (zingiberene), and 6-gingerol (0.1-0.3%), 8-gingerol, 10-gingerol, zingerone, 6-show Autumn (6 ᅳ shogaol, 0.04%) and gamma-aminobutyric ' acid. Extraction of natural products by supercritical fluids has been of great interest. Extraction and separation techniques using supercritical fluids are one of the separation techniques for selectively extracting specific components from the mixed components using the unique physical properties of the supercritical fluid in the region near or beyond the critical point.
흔합물에서 특정성분을 분리하는 방법에는 구성성분의 휘발도 차이를
이용하는 증류법과 특정 용매에 대한 용해도 차이를 이용하는 용매추출법 등이 있다. 증류법은 높은 비점에서 조작됨으로 천연물의 증류에서는 고온에 의한 유효성분의 분해와 파괴 등이 문제가 된다. 용매추출법은 적절한 유기용제의 선정, 추출상에 유기용제의 잔존 및 제거공정의 필요， 낮은 분리효과 등의 어려움이 수반된다. 그러나 초임계 유체 추출법은 증류법에 비하여 임계온도 부근의 저온에서 조작이 가능하므로 저에너지 소비공정이며 천연물과 같이 열에 민감한 물질에 적용하기 좋다. 또 용매추출법과 비교하여 볼 때 초임계 유체는 확산계수가 크고 점도가 낮아 추출속도가 빠르며 상분리가 용이하여 용매추출법처럼 잔존용매의 제거공정이 필요 없다. 생강은 여러 기능성을 나타내지만 이를 활용한 다양한 기능성 식품이나 염증 치료용 약학 조성물을 개발하고자 할 때 기호적으로 양호하지 않은 맛과 특유의 향기 특성을 나타내기 때문에 제약이 따른다. 따라서 생강 특유의 맛과 향기를 제거하거나 보완할 수 있을 뿐 아니라 짧은 시간 안에 추출 수율을 높으면서도 항염 활성성분 중 하나인 진저를 (gingerol)의 함량이 높은 추출물을 얻는 추출방법의 개발이 필요한 실정이다ᅳ 또한， 생강 추출물뿐 아니라 생강을 초임계 추출하고 남은 생강박의 활용방법에 대한 개발이 필요하다. 이에 본 발명자들은 종래기술의 문제점을 해결하기 위해 예의 연구한 결과, 초임계 추출법을 이용하면 진저를의 함량의 높은 생강 추출물을 제조할 수 있을뿐만 아니라， 초임계 생강 추출물과 남은 생각박의 추출물이 높은 항염 및 항알러지 활성을 있음을 확인하고, 본 발명을 완성하였다. Separation of specific components from the mixture involves the difference in volatility of the components. Distillation method and solvent extraction method using the difference in solubility in a specific solvent. Distillation is operated at a high boiling point, so in the distillation of natural products, decomposition and destruction of the active ingredient due to high temperature becomes a problem. Solvent extraction involves difficulties in selecting an appropriate organic solvent, remaining organic solvent in the extraction phase, the need for a removal process, and low separation effect. However, the supercritical fluid extraction method is a low energy consumption process because it can be operated at a low temperature near the critical temperature compared to the distillation method and is suitable for heat sensitive materials such as natural products. Compared with the solvent extraction method, the supercritical fluid has a high diffusion coefficient and low viscosity, so the extraction speed is fast, and phase separation is easy. Therefore, the residual solvent removal process is not required like the solvent extraction method. Ginger exhibits various functionalities, but when it develops various functional foods or pharmaceutical compositions for treating inflammation using the same, it is restricted in preference because it exhibits taste and characteristic aroma characteristics. Therefore, it is necessary to develop an extraction method that can not only remove or supplement the unique flavor and aroma of ginger but also increase the extraction yield in a short time, but also obtain an extract with a high content of ginger (Gingerol), one of the anti-inflammatory active ingredients. ᅳ It is also necessary to develop not only ginger extract but also how to use the remaining ginger foil after supercritical extraction of ginger. Accordingly, the present inventors have studied diligently to solve the problems of the prior art, and as a result of using the supercritical extraction method, it is possible to prepare a ginger extract having a high content of ginger, as well as a supercritical ginger extract and an extract of the remaining idea It was confirmed that the high anti-inflammatory and anti-allergic activity, the present invention was completed.
[발명의 상세한 설명] Detailed description of the invention
【기술적 과제】 [Technical problem]
본 발명은 생강 분말을 초임계 이산화탄소를 이용하여 35 - 55°C의 온도， 100~ 400 bar의 압력에서 1 ~ 3 mL/min의 유속으로 1 ~ 3 시간 동안 초임계 추출하여 생강유를 얻는 것을 특징으로 하는 생강 추출물 제조방법을 제공한다.
본 발명은 또한， 상기 생강유를 얻은 후 남은 박을 생강 박 무게에 대하여 5 ~ 15배 (w/v)의 60 ~ 90% 주정을 가하고 실온에서 6 - 36시간 동안 정치하는 것을 특징으로 하는 생강 추출물 제조방법을 제공한다. 본 발명은 생강 특유의 맛과 향기를 제거하거나 보완할 수 있을 뿐 아니라 짧은 시간 안에 추출 수율이 높으면서도 진저롤 (gingerol)의 함량이 높은 추출물을 얻을 수 있는 생강 추출물 제조방법을 제공한다. 본 발명은 생강올 초임계 추출하고 남은 생강박을 활용하여 항염 및 항알러지 활성이 높은 생강 추출물， 또는 이를 이용한 항염 및 항알러지 용도를 제공한다. 【기술적 해결방법】 The present invention is to obtain ginger oil by supercritical extraction of ginger powder for 1 to 3 hours at a flow rate of 1-3 mL / min at a temperature of 35-55 ° C, pressure of 100 ~ 400 bar using supercritical carbon dioxide It provides a method for producing ginger extract characterized in that. The present invention is also characterized in that the ginger remaining after obtaining the ginger oil is added to 60 ~ 90% alcohol of 5 to 15 times (w / v) with respect to the weight of ginger foil and allowed to stand for 6 to 36 hours at room temperature It provides a method for producing an extract. The present invention provides a ginger extract manufacturing method which can not only remove or supplement the unique flavor and aroma of ginger but also obtain a high extracting yield in a short time, but also a high content of gingerol (gingerol). The present invention provides a ginger extract with high anti-inflammatory and anti-allergic activity, or anti-inflammatory and anti-allergic uses using the same, using the remaining ginger foil after gingerol supercritical extraction. Technical Solution
이에 본 발명은 바람직한 게 1구현예로서 (S1) 생강 분말을 준비하는 단계; 및 (S2) 생강 분말을 초임계 이산화탄소를 이용하여 35 ~ 55°C의 온도, 100~ 400 bar의 압력에서 1 ~ 3 mL/niin의 유속으로 1 ~ 3 시간 동안 초임계 추출법으로 추출하여 생강유를 얻는 단계;를 포함하는 생강 추출물 제조방법을 제공한다. 상기 구현예에 의한 생강 초임계 추출물 제조방법에서, (S1) 단계에서의 생강 분말은 평균 입도가 50 ~ 500 μηι인 생강 추출물 제조방법을 제공한다. 상기 구현예에 의한 생강 초임계 추출물 제조방법에서， 추출 수율이 2.5 - 3.0중량%인 생강 추출물 제조방법을 제공한다. 상기 구현예에 의한 생강 초임계 추출물 제조방법에서， (S2) 단계 이후에 (S3) 생강유를 얻은 후 남은 박을 생강 박 무게에 대하여 5 ~ 15배 (w/v)의 60 ~ 90% 주정을 가하고 실온에서 6 ~ 36시간 동안 정치하는 단계; 및 (S4) 여과 및 농축하는 단계;를 더 포함하는 생강 추출물 제조방법을 제공한다.
본 발명은 바람직한 게 2구현예로서 상기의 제조방법에 따라 제조된 생강 추출물을 제공한다. 상기 제 2구현예에 의한 생강 초임계 추출물에서， 진저를 (gingerol)의 함량이 21 ~ 25중량 )인 생강 추출물을 제공한다. 상기 제 2구현예에 의한 생강 추출물에서, 10 ~ 100/g/mL의 농도에서 NOCNitric Oxide) 생성 억제 효과가 50 ~ 98%인 생강 추출물을 제공한다. 본 발명은 바람직한 제 3구현예로서 상기 생강 추출물을 포함하는 항염증 조성물을 제공한다. 본 발명은 바람직한 게 4구현예로서 상기 생강 추출물을 포함하는 항알러지 조성물을 제공한다. 이하, 본 발명을 더욱 상세히 설명한다. Therefore, the present invention is to prepare a ginger powder (S1) as a preferred embodiment; And (S2) ginger powder by using supercritical carbon dioxide extracted by supercritical extraction method for 1 to 3 hours at a temperature of 35 to 55 ° C, pressure of 100 to 400 bar at a flow rate of 1 to 3 mL / niin It provides a method for producing ginger extract comprising; step of obtaining. In the ginger supercritical extract manufacturing method according to the embodiment, the ginger powder in the step (S1) provides a ginger extract manufacturing method having an average particle size of 50 ~ 500 μηι. In the ginger supercritical extract manufacturing method according to the embodiment, the extraction yield is 2.5 to 3.0% by weight to provide a ginger extract manufacturing method. In the ginger supercritical extract manufacturing method according to the above embodiment, after the step (S2) (S3) after the ginger oil obtained after the remaining 5 to 15 times (w / v) 60 ~ 90% alcohol Adding and standing at room temperature for 6 to 36 hours; And (S4) filtration and concentration; provides a ginger extract manufacturing method further comprising. The present invention provides a ginger extract prepared according to the above production method as a preferred embodiment two. In the ginger supercritical extract according to the second embodiment, a ginger extract having a content of ginger (21 to 25 weight) is provided. In the ginger extract according to the second embodiment, it provides a ginger extract 50 to 98% of the NOCNitric Oxide) inhibitory effect at a concentration of 10 ~ 100 / g / mL. The present invention provides an anti-inflammatory composition comprising the ginger extract as a third preferred embodiment. The present invention provides an anti-allergic composition comprising the ginger extract as a preferred embodiment. Hereinafter, the present invention will be described in more detail.
본 발명은 초임계 추출방법을 이용하여 항염 효과가 높은 생강 추출물을 제조하는 방법 및 이에 따른 생강 추출물을 제공하는 것으로， 특히 생강 분말을 초임계 이산화탄소를 이용하여 35 ~ 55°C의 온도, 100~ 400 bar의 압력에서 1 ~ 3 mL/min의 유속으로 1 ~ 3 시간 동안 초임계 추출함으로써， 생강 특유의 맛과 향기를 제거하거나 보완할 수 있을 뿐 아니라 짧은 시간 안에 추출 수율이 높으면서도 진저를 (gingerol)의 함량이 높은 추출물을 얻는 방법을 제공한다. 상기 각각의 조건들이 범위를 벗어날 경우， 추출 수율이 낮아지거나 추출 수율이 더 이상 증가하지 않아 경제적으로 바람직하지 못하다. 또한， 본 발명은 상기 초임계 추출 후 남은 생강 박을 박 무게에 대하여 5 ~ 15배 (w/v)의 60 ~ 90% 주정을 가하고 실온에서 6 - 36시간 동안 정치시킴으로써， 생강박을 활용하여 항염 활성이 높은 생강 추출물을 얻는 방법을 제공한다. 여기서， 주정은 에탄을 (Ethanol) 또는 에틸알코을 (Ethyle Alcohol)과 동일한 의미로 사용되며， 주정은 곡물을
원료로 미생물이나 효소에 의해 발효하여 증류 생산한 발효주정과 석유나 석탄에서 얻은 에틸렌올 원료로 하여 생산한 합성주정으로 구분될 수 있다. 이를 위하여 본 발명은 (S1) 생강 분말을 준비하는 단계; 및 (S2) 생강 분말을 초임계 이산화탄소를 이용하여 35 ~ 55°C의 온도， 100 ~ 400 bar의 압력에서 1 ~ 3 mL/min의 유속으로 1 ~ 3 시간 동안 초임계 추출법으로 추출하여 생강유를 얻는 단계;를 포함하는 생강 추출물 제조방법을 제공한다. 먼저， (S1) 단계에서는 생강 분말을 준비한다. 생강 분말은 평균 입도가 50 - 500 μηι인 것이 추출속도가 높으므로 바람직하다. The present invention provides a method for producing a ginger extract having a high anti-inflammatory effect by using a supercritical extraction method and a ginger extract accordingly, in particular the ginger powder using a supercritical carbon dioxide temperature of 35 ~ 55 ° C, 100 ~ Supercritical extraction for 1-3 hours at a flow rate of 1-3 mL / min at a pressure of 400 bar not only eliminates or complements the ginger's distinctive flavor and aroma, but also provides a high yield of extract in a short time ( It provides a method of obtaining an extract with a high content of gingerol). If the respective conditions are out of range, the extraction yield is lowered or the extraction yield is no longer increased, which is economically undesirable. In addition, the present invention by adding a 60 ~ 90% alcohol of 5 to 15 times (w / v) to the weight of the gourd ginger gourd remaining after the supercritical extraction and allowed to stand for 6 to 36 hours at room temperature, using the ginger gourd Provided is a method for obtaining ginger extract with high anti-inflammatory activity. Here, alcohol is used in the same sense as Ethanol or Ethyle Alcohol, and alcohol is used for grain. It can be divided into fermentation alcohol distilled and fermented by microorganisms or enzymes as a raw material and synthetic alcohol produced by ethyleneol raw material obtained from petroleum or coal. To this end, the present invention comprises the steps of preparing a ginger powder (S1); And (S2) ginger powder is extracted by supercritical extraction for 1 to 3 hours at a flow rate of 1 to 3 mL / min at a temperature of 35 to 55 ° C and a pressure of 100 to 400 bar using supercritical carbon dioxide. It provides a method for producing ginger extract comprising; step of obtaining. First, in step (S1) to prepare a ginger powder. Ginger powder is preferred to have an average particle size of 50-500 μηι because of its high extraction rate.
(S2) 단계에서는 상기 생강 분말을 초임계 이산화탄소를 이용하여 35 ~ 55°C의 온도， 100 ~ 400 bar의 압력에서 1 ~ 3 mL/min의 유속으로 1 ~ 3 시간 동안 초임계 추출법으로 추출한다. In the step (S2), the ginger powder is extracted by supercritical extraction for 1 to 3 hours at a flow rate of 1 to 3 mL / min at a temperature of 35 to 55 ° C and a pressure of 100 to 400 bar using supercritical carbon dioxide. .
상기 추출방법에 의하면 생강유 (생강 초임계 추출물)를 짧은 시간 안에 2.5 ~ 3.0증량%의 수율로 얻을 수 있다. According to the extraction method, ginger oil (ginger supercritical extract) can be obtained in a yield of 2.5 to 3.0% by weight in a short time.
그리고, 상기 추출방법에 의하면 항염 활성성분 증 하나인 진저롤 (gingerol)의 함량이 21 ~ 25중량 %인 생강 추출물을 얻을 수 있다. 즉， 상기 조건으로 생강 분말을 초임계 추출하는 경우 생강 특유의 맛과 향기를 제거하거나 보완할 수 있을 뿐 아니라 짧은 시간 안에 추출 수율을 높으면서도 진저를 (gingerol)의 함량이 높은 추출물 (생강유)을 얻을 수 있다. 또한, 본 발명의 생강 추출물 제조방법은 상기 (S2) 단계 이후에, In addition, according to the extraction method, a ginger extract having a content of 21 to 25% by weight of gingerol, which is one of the anti-inflammatory active ingredients, can be obtained. In other words, when the supercritical extraction of ginger powder under the above conditions, it is possible not only to remove or supplement the flavor and aroma unique to ginger, but also to extract a high content of ginger in a short time (gingerol) extract (ginger oil) Can be obtained. In addition, the ginger extract manufacturing method of the present invention after the (S2) step,
(S3) 생강유를 얻은 후 남은 박을 생강 박 무게에 대하여 5 ~ 15배 (w/v)의 60 ~ 90% 주정을 가하고 실온에서 6 ~ 36시간 동안 정치하는 단계; 및 (S4) 여과 및 농축하는 단계;를 더 포함할 수 있다. (S3) adding remaining oil after ginger oil is added 5 to 15 times (w / v) of 60 to 90% spirits and weighing 6 to 36 hours at room temperature; And (S4) filtering and concentrating.
그리고, 상기 방법에 의하면 생강을 초임계 추출하고 생강박을 활용하여 10 ~ 100 g/mL의 농도에서 N0(Nitric Oxide) 생성 억제 효과가 50 ~ 98%인 생강 추출물을 얻을 수 있다. 즉， 상기 추출방법에 의하면 생강을
초임계 추출하고 남은 생강박을 활용하여 항염 및 항알러지 활성이 높은 생강 추출물을 얻을 수 있다. 염증반웅이 일어나면 여러 가지 염증인자들 (proinflammatory mediators)이 만들어지는데， 염증인자에는 inducible nitric oxide synthase(iNOS)에 의해서 만들어지는 NCKNitric Oxide)와 cyclooxygenase_2 (C0X-2)에 의해서 만들어지는 prostaglandin E2(PGE2) 등이 있다. 이러한 염증 인자는 염증반웅의 전사인자인 nuclear f actor-kB(NF-kB)를 활성화시키며, 그 결과 과량의 NO와 PGE2를 생성하여 염증을 일으킨다. 따라서， N0(Nitric Oxide)의 생성을 억제하면 염증 반웅을 억제할 수 있게 된다. 제 1형 과민반웅은 비만세포에 의해 매개되는 알러지 반웅으로서， 예기치 못한 알러젠에 의해 비만세포가 활성화 되어 탈 과립 되면서 히스타민등과 같은 여러 가지 매개체들을 분비하면서 과도하게 면역반웅을 유도하게 된다. 본 발명에서는 생강 추출물을 이용하여 비만세포에서의 탈과립 억제 효과를 측정하였다. 그 결과 본 발명에 따른 생강 추출물이 탈과립의 표지인 β -hexosaminidase의 방출량을 농도 의존적으로 억제하는 것을 관찰하였다. 이러한 결과는 본 발명에 따른 생강 추출물 항 알러지 약물의 개발에 잠재적인 후보물질이 될 수 있음을 시사한다. 다음으로， 본 발명은 상기한 생강 추출물 제조방법에 따른 생강 추출물을 포함하는 항염증 조성물을 제공한다. 본 발명의 실시예에서는 본 발명에 따른 생강 추출물이 염증인자인 N0(Nitric Oxide) 생성 억제 효과 및 항염증성 단백질인 heme oxygenase(H0)-l의 발현 증가 효과가 우수함을 입증하였다. 다음으로， 본 발명은 상기한 생강 추출물 제조방법에 따른 생강 추출물을 포함하는 항알러지 조성물을 제공한다. 본 발명의 실시예에서는 본 발명에 따른 생강 추출물이 알러지 반웅을 일으키는 비만세포 탈과립의 마커 효소인 beta— hexosaminidase의 방출 억제 효과가 우수함을 입증하였다.
상기 항염증 또는 항알러지 조성물은 기능성 화장료 조성물, 약학 조성물， 식품 조성물 등 다양한 산업 분야에 활용될 수 있어 매우 유용한 발명이다. 본 발명의 기능성 화장료 조성물에 포함되는 성분은 유효 성분으로서의 생강 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함하며 , 예컨대 용매， 안정화제， 용해화제 , 유화제 , 비타민 안료 및 향료와 같은 통상적인 보조제， 그리고 담체를 포함할 수 있다. In addition, according to the above method, a ginger extract having a supercritical extraction of ginger and 50 to 98% of N0 (Nitric Oxide) production inhibitory effect at a concentration of 10 to 100 g / mL can be obtained using ginger foil. That is, according to the extraction method ginger Ginger extract with high anti-inflammatory and anti-allergic activity can be obtained by using the remaining ginger foil after supercritical extraction. Inflammatory reactions produce a variety of proinflammatory mediators, including prostaglandin E 2 (PGE) produced by NCKNitric Oxide) and cyclooxygenase_2 (C0X-2) produced by inducible nitric oxide synthase (iNOS). 2 ) and so on. These inflammatory factors activate nuclear f actor-kB (NF-kB), a transcription factor of inflammatory reactions, resulting in excessive NO and PGE 2 inflammation. Therefore, by inhibiting the production of NO (Nitric Oxide) it is possible to suppress the inflammatory reaction. Type I hypersensitivity reactions are allergic reactions mediated by mast cells, which induce excessive immune response while secreting various mediators such as histamine as the mast cells are activated and de-granulated by unexpected allergens. In the present invention, the inhibitory effect of degranulation in mast cells was measured using ginger extract. As a result, it was observed that the ginger extract according to the present invention inhibits the release amount of β-hexosaminidase, which is a label of degranulation, in a concentration-dependent manner. These results suggest that ginger extract can be a potential candidate for the development of anti-allergic drugs. Next, the present invention provides an anti-inflammatory composition comprising a ginger extract according to the ginger extract manufacturing method. In the embodiment of the present invention it was proved that the ginger extract according to the present invention has an excellent effect of inhibiting the production of inflammatory factor NO (Nitric Oxide) and increasing the expression of the anti-inflammatory protein heme oxygenase (H0) -1. Next, the present invention provides an anti-allergic composition comprising a ginger extract according to the ginger extract manufacturing method. In the embodiment of the present invention, the ginger extract according to the present invention demonstrated that the release inhibitory effect of beta-hexosaminidase, a marker enzyme of mast cell degranulation causing allergic reaction. The anti-inflammatory or anti-allergic composition is a very useful invention because it can be utilized in various industrial fields such as functional cosmetic compositions, pharmaceutical compositions, food compositions. The components included in the functional cosmetic composition of the present invention include components commonly used in cosmetic compositions in addition to ginger extract as an active ingredient, and include conventional auxiliaries such as solvents, stabilizers, solubilizers, emulsifiers, vitamin pigments and flavorings, And a carrier.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으나， 바람직하게는， 화장수， 영양로션， 영양크림, 맛사지크림， 영양에센스， 팩， 메이컵베이스， 파운데이션， 바디오일， 헤어오일, 샴프， 린스로 구성된 군에서 선택된 제형으로 제조되는 것을 특징으로 한다. 이러한 화장료 조성물의 제형예에 상관없이 본 발명의 생강 추출물올 함유하는 한 본 발명의 항염증효과 및 항알러지효과를 가지며， 피부에 발생한 자유라디칼을 소거하고 세포내 항산화계 보호효과가 있어 자유라디칼 등의 작용에 의한 산화에 의하여 발생하는 피부 노화의 예방 및 지연 효과를 발휘할 수 있다. 본 발명의 약학적 조성물은 정제, 발포성 정제, 캡슐제， 과립거 1 산제, 서방성 정제， 서방성 캡슐제 (단독 및 복합 단위 제제)， 정맥 내 및 근육 내 주사용 앰플제 형태의 주사제， 현탁액， 좌제, 또는 기타 적합한 약제학적 형태로 투여할 수 있다. The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, but preferably, lotion, nutrition lotion, nutrition cream, massage cream, nutrition essence, pack, makeup base, foundation, body oil ， Hair oil, shampoo, rinse characterized in that it is made of a formulation selected from the group consisting of. Irrespective of the formulation of the cosmetic composition, as long as it contains the ginger extract of the present invention, it has the anti-inflammatory and anti-allergic effect of the present invention, eliminates free radicals generated in the skin, and has an intracellular antioxidant protection effect, thus free radicals. It can exert the effect of preventing and delaying skin aging caused by oxidation by the action of. The pharmaceutical compositions of the present invention may be used in the form of tablets, effervescent tablets, capsules, granulone powder, sustained-release tablets, sustained-release capsules (alone and complex unit preparations), injections in the form of ampoules for intravenous and intramuscular injection, suspensions Or suppositories, or other suitable pharmaceutical forms.
상기 약학적 조성물을 함유하는 약제학적 제제를 제조하기 위해서， 생강 추출물은 생리학적으로 내성이 있는 부형제 및 /또는 희석제 및 /또는 보조제와 함께 바람직한 방식으로 지시된 양으로 제형화될 수 있다. 적합한 부형제 및 보조제의 예는 다음 문헌을 참조할 수 있다 (Dr. H.P. Fiedler "Lex ikon der Hi lfsstof fe fur Pharmaz i e , Kosmet i k und angrenzende Gebiete" [Encyclopaedia of auxiliaries for pharmacy, cosmetics and related fields] . To prepare a pharmaceutical formulation containing the pharmaceutical composition, ginger extract may be formulated in the indicated amounts in a preferred manner with physiologically resistant excipients and / or diluents and / or adjuvants. Examples of suitable excipients and auxiliaries can be found in Dr. H.P. Fiedler "Lex ikon der Hi lfsstof fe fur Pharmaz i e, Kosmet i k und angrenzende Gebiete" [Encyclopaedia of auxiliaries for pharmacy, cosmetics and related fields].
본 발명의 약학적 조성물은 항염 및 항알러지의 치료 또는 예방을 필요로 하는 개체에 약학적 유효량으로 투여될 수 있으며， 상기 유효량은
바람직하게는 상기 활성성분인 생강 추출물을 기준으로 성인에게 l/g/kg/일 내지 400mg/kg/일 투여할 수 있으몌 질병의 심각정도에 따라 증감할 수 있다. 【유리한 효과】 The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount to an individual in need of treatment or prevention of anti-inflammatory and anti-allergy, wherein the effective amount is Preferably it can be administered to l / g / kg / day to 400 mg / k g / day to adults based on the ginger extract of the active ingredient can be increased or decreased depending on the severity of the disease. Advantageous Effects
본 발명은 생강을 특정 조건으로 초임계 추출함으로써 생강 특유의 맛과 향기를 제거하거나 보완할 수 있을 뿐 아니라 짧은 시간 안에 추출 수율을 높으면서도 진저롤 (gingerol)의 함량이 높은 추출물을 얻을 수 있어 식품산업에 매우 유용한 발명이다. 또한, 본 발명은 상기 초임계 추출 후 남은 생강박을 활용하여 항염 및 항알러지 활성이 높은 생강 추출물을 얻을 수 있다. According to the present invention, the supercritical extraction of ginger under specific conditions can remove or supplement the unique flavor and aroma of ginger, as well as obtain an extract with a high content of gingerol in a short time, while obtaining a high content of gingerol. Is a very useful invention. In addition, the present invention can be obtained by using the ginger leaves remaining after the supercritical extraction ginger extract with high anti-inflammatory and anti-allergic activity.
【도면의 간단한 설명】 [Brief Description of Drawings]
도 1은 본 발명의 바람직한 일 실시예에 따라 생강의 초임계 추출 온도와 압력별 수율 변화를 나타내는 그래프이다. 1 is a graph showing a change in yield of each supercritical extraction temperature and pressure of ginger according to an embodiment of the present invention.
도 2는 본 발명의 바람직한 일 실시예에 따라 35°C의 온도에서 압력을 달리하여 추출한 생강 추출물의 외관을 나타내는 사진이다. Figure 2 is a photograph showing the appearance of the ginger extract extracted by varying the pressure at a temperature of 35 ° C in accordance with a preferred embodiment of the present invention.
도 3은 본 발명의 바람직한 일 실시예에 따라 초임계 추출 온도와 압력을 달리하여 추출한 생강 추출물의 항산화 활성을 비교하여 나타낸 그래프이다. 이때, 도 3a는 35°C에서 초임계 추출한 생강 추출물의 항산화 활성을 나타낸 것이고， 도 3b는 45 °C, 도 3c는 55°C에서 초임계 추출한 생강 추출물의 항산화 활성을 나타낸 그래프이다. Figure 3 is a graph showing the antioxidant activity of the ginger extract extracted by varying the supercritical extraction temperature and pressure according to an embodiment of the present invention. At this time, Figure 3a shows the antioxidant activity of the supercritical extract ginger extract at 35 ° C, Figure 3b is 45 ° C, Figure 3c is a graph showing the antioxidant activity of the supercritical extract ginger extract at 55 ° C.
도 4는 본 발명의 바람직한 일 실시예에 따른 생강 초임계 추출물의 세포독성 및 NO 소거능을 나타내는 그래프이다. 구체적으로, 도 4a는 생강 초임계 추출물의 세포독성을 나타내는 그래프이고， 도 4b는 생강 초임계 추출물의 NO 소거능을 나타내는 그래프이다. Figure 4 is a graph showing the cytotoxicity and NO scavenging ability of the ginger supercritical extract according to an embodiment of the present invention. Specifically, Figure 4a is a graph showing the cytotoxicity of the ginger supercritical extract, Figure 4b is a graph showing the NO scavenging ability of the ginger supercritical extract.
도 5는 본 발명의 바람직한 일 실시예에 따른 생강 초임계 박추출물의 세포독성 및 NO 소거능을 나타내는 그래프이다. 구체적으로， 도 5a는 생강 초임계 박추출물의 세포독성을 나타내는 그래프이고， 도 5b는 생강 초임계 박 추출물의 N0소거능을 나타내는 그래프이다. Figure 5 is a graph showing the cytotoxicity and NO scavenging ability of ginger supercritical extract according to an embodiment of the present invention. Specifically, Figure 5a is a graph showing the cytotoxicity of the ginger supercritical extract, Figure 5b is a graph showing the N0 scavenging ability of the ginger supercritical gourd extract.
도 6은 본 발명의 바람직한 비교예에 따른 생강 에탄을 추출물의
세포독성 및 NO 소거능을 나타내는 그래프이다. 구체적으로， 도 6a는 생강 에탄을 추출물의 세포독성을 나타내는 그래프이고, 도 6b는 생강 에탄올 추출물의 NO 소거능을 나타내는 그래프이다. Figure 6 of the extract of ginger ethane according to a preferred comparative example of the present invention Graph showing cytotoxicity and NO scavenging activity. Specifically, Figure 6a is a graph showing the cytotoxicity of the extract of ginger ethane, Figure 6b is a graph showing the NO scavenging ability of the ginger ethanol extract.
도 7은 진저를 (gingerol)의 세포독성 및 NO 소거능을 나타내는 그래프이다. 구체적으로， 도 7a는 진저를의 세포독성을 나타내는 그래프이고， 도 7b는 진저를의 NO소거능을 나타내는 그래프이다. 7 is a graph showing the cytotoxicity and NO scavenging ability of ginger. Specifically, Figure 7a is a graph showing the cytotoxicity of ginger, Figure 7b is a graph showing the NO activating ability of ginger.
도 8은 본 발명의 바람직한 일 실시예에 따른 생강 초임계 박추출물의 heme oxygenase (H0)-1 발현 증가 효과를 나타내는 그래프이다. 도 9은 본 발명의 바람직한 일 실시예에 따른 생강 초임계 추출물 및 박 추출물의 beta— hexosaminidase 방출 억제 효과를 나타내는 그래프이다. 구체적으로, 도 9a는 생강 초임계 추출물의 beta-hexosaminidase 방출 억제 효과를 나타내는 그래프이고， 도 9b는 생강 초임계 박추출물의 beta- hexosaminidase 방출 억제 효과를 나타내는 그래프이다. 【발명의 실시를 위한 최선의 형태】 8 is a graph showing the effect of increasing heme oxygenase (H0) -1 expression of ginger supercritical thin extract according to an embodiment of the present invention. Figure 9 is a graph showing the beta-hexosaminidase release inhibitory effect of the ginger supercritical extract and gourd extract according to an embodiment of the present invention. Specifically, Figure 9a is a graph showing the inhibitory effect of beta-hexosaminidase release of ginger supercritical extract, Figure 9b is a graph showing the inhibitory effect of beta-hexosaminidase release of ginger supercritical extract. [Best form for implementation of the invention]
이하, 본 발명의 구성을 실시예를 통하여 보다 상세히 설명하나， 본 발명의 범위가 하기 실시예로 한정되는 것은 아니다. Hereinafter, the configuration of the present invention in more detail through examples, but the scope of the present invention is not limited to the following examples.
[실시예] 실시예 1 EXAMPLES Example 1
초임계유체추출장치 (SFT-IOOXW, Supercritical Fluid Technologies, Inc. , Newark, DE, USA)를 사용하였고， 평균입도가 50 - 500 μηι인 생강 분말 18g을 100 mL의 용량의 추출조에 넣어 추출하였다. 시료의 추출조건은 35， 45, 55 °C온도에서 100， 200, 300， 400 bar로 압력을 변화시키며 실시하였고， 이산화탄소의 유속은 2 mL/min로 다이나믹 모드에서 2시간동안 추출하여 추출물을 곧바로 용기 (vial)에 받아내었다. 실시예 2 A supercritical fluid extractor (SFT-IOOXW, Supercritical Fluid Technologies, Inc., Newark, DE, USA) was used, and 18 g of ginger powder having an average particle size of 50-500 μηι was extracted in an extraction tank having a volume of 100 mL. The extraction conditions of the samples were carried out at 35, 45, 55 ° C and 100, 200, 300, 400 bar at varying pressures. The flow rate of carbon dioxide was extracted at 2 mL / min for 2 hours in dynamic mode. Received in a vial. Example 2
실시예 1에서 생강 초임계 추출물 (생강유)을 얻고 남은 부산물인 생강박의 무게에 대하여 10배 (w/v)의 70% 주정을 가하고 실온에서 24시간
동안 정치하여 생강 (박) 추출물을 얻었다. 비교예 In Example 1, a ginger supercritical extract (ginger oil) was obtained and 10 times (w / v) of 70% alcohol was added to the weight of the remaining by-product ginger foil, followed by 24 hours at room temperature. It was left to stand to obtain a ginger (bak) extract. Comparative example
평균입도가 50 - 500 μηι인 생강 분말에 상기 생강 분말 무게에 대하여 10배 (w/v)의 70% 주정 (에탄을)을 가하고 실온에서 24시간 동안 정치하여 생강 추출물을 얻었다. To a ginger powder having an average particle size of 50-500 μηι, 10 times (w / v) of 70% spirit (ethane) was added to the ginger powder weight and left at room temperature for 24 hours to obtain a ginger extract.
[실험예] 실험예 1: 생강의 초임계 추출 수율 Experimental Example 1 Supercritical Extraction Yield of Ginger
생강의 초임계 추출 수율은 도 1에 나타낸 바와 같이 동일한 온도에서는 압력이 증가할수록 증가하는 것으로 나타났으며， 100 bar에서는 온도가 351：에서 55°C로 증가할수록 수율이 1.91%에서 1.07%로 감소한 반면 200-400 bar에서는 온도가 증가할수록 추출수율이 증가하여 55°C의 경우 각각 2.41， 2.92, 3.00%를 나타내었다. 실험예 2: 생강 추출물의 색도 및 외관 As shown in Fig. 1, the supercritical extraction yield of ginger increased with increasing pressure at the same temperature, and the yield decreased from 1.91% to 1.07% at 100 bar as the temperature increased from 351 to 55 ° C. On the other hand, at 200-400 bar, the extraction yield increased as the temperature increased, indicating 2.41, 2.92 and 3.00%, respectively, at 55 ° C. Experimental Example 2: Color and Appearance of Ginger Extract
색도는 color and color difference meter(Color QUEST Π , Hunter Lab, USA)를 이용하여 L( 1 ightness) , a(redness/greenness) , Myellowness/blueness)값을 측정하였으며， 이때 표준 백색판은 L=92.68, a=-0.81, b=0.86의 값을 가진 것을 사용하였다. The chromaticity was measured by using a color and color difference meter (Color QUEST Π, Hunter Lab, USA) to measure L (1ightness), a (redness / greenness), and Myellowness / blueness. , a = -0.81 and b = 0.86 were used.
도 2는 35°C에서 압력을 달리하여 추출한 생강 추출물의 외관을 나타낸 것으로， 100 bar에서는 노란색을 나타내었고 압력이 증가할수록 생강 고유의 색소성분이 많이 추출되어 색이 진하여지면서 400 bar에서는 붉은 계통의 적갈색을 나타내었다. 또한, 초임계 추출조건에 따른 생강 추출물의 색도 측정 결과 하기 표 1에서 나타낸 바와 같이 모든 온도조건에서 압력이 증가함에 따라 L 값과 b 값이 크게 감소하였으며 특히 b 값의 감소가 큰 것으로 나타나 생강의 색소 추출과 b 값의 관련성이 가장 큰 것을 알 수 있었다.
【표 1】 Figure 2 shows the appearance of the ginger extract extracted by varying the pressure at 35 ° C, it was yellow at 100 bar and as the pressure increases, a lot of ginger's unique pigment components are extracted, the color becomes darker, the red system at 400 bar It is reddish brown. In addition, as a result of measuring the chromaticity of the ginger extract according to the supercritical extraction condition, as shown in Table 1, the L value and the b value decreased significantly with increasing pressure at all temperature conditions. It was found that the correlation between the pigment extraction and the b value was the largest. Table 1
초임계 추출 온도와 압력별 생강 추출물의 색도 Color of Ginger Extract by Supercritical Extraction Temperature and Pressure
생강 초임계 추출물에 함유된 6-진저롤 (6-gingerol), 8-진저롤 (8- gingerol), 10-진저를 (10-gingerol )， 6-쇼가을 (6-shogaol ) 등의 진저롤 (gingerol)의 함량올 HPLCCJasco Co., Japan)를 이용하여 정량하였다. 컬럼은 Waters symmetry C—8 reversed phase column (150 x 3.9 mm, Cat . No. WAT0 54235)을 이용하였고， 이동상은 methanol_water(46:35, v/v)를 1 mL/min의 속도로 용출하였으며, 시료의 검출은 UV detecter로 282 nm에서 측정하였다. 분석표준물질인 6-진저를， 8—진저를, 10-진저롤， 6-쇼가올은 크로마텍스 (Chromadex)사에서 구입하여 사용하였다. 실시예 1의 생강 추출물을 5 mg/mL 농도로 메탄올에 녹인 후 0.45 μιη syringe filter(Millipore)로 여과하여 제조하였고 이를 분석용 시료로 사용하였다.
초임계 추출 온도와 압력별 생강 추출물의 진저롤 함량 변화를 측정한 결과는 하기 표 2에 나타내었다. 진저롤 함량 분포는 6-진저롤이 가장 높은 함량을 나타내었고 (10.78~17.17%) 8-진저를 (2.38~4.08>)， 10- 진저롤 (1.01~3.07¾))， 6-쇼가올 (0.64~1.09%)의 순으로 나타났다. 추출온도와 상관없이 100 bar에서 가장 낮은 진저를 함량을 나타내었고 추출온도가 증가할수록 각각 20.00， 18.02, 15.13%로 낮아지는 경향이었다. 반면 200~400 bar의 범위에서는 21.46-24.48%로서 큰 차이가 없는 진저를 (gingerol) 함량을 나타내었다. Gingerol, such as 6-gingerol, 8-gingerol, 10-gingerol and 6-shogaol, contained in ginger supercritical extract The content was determined using HPLCC Jasco Co., Japan). The column used a Waters symmetry C-8 reversed phase column (150 x 3.9 mm, Cat. No. WAT0 54235), and the mobile phase eluted methanol_water (46:35, v / v) at a rate of 1 mL / min. Detection of the sample was measured at 282 nm with a UV detector. Analytical standard 6-Ginger, 8-Ginger, 10-Gingerol and 6-Shogaol were purchased from Chromadex. The ginger extract of Example 1 was dissolved in methanol at a concentration of 5 mg / mL and filtered by 0.45 μιη syringe filter (Millipore), which was used as a sample for analysis. The results of measuring the ginger roll content change of ginger extract according to supercritical extraction temperature and pressure are shown in Table 2 below. Ginger roll content distribution showed the highest content of 6-ginger roll (10.78 ~ 17.17%), 8-ginger (2.38 ~ 4.08>), 10- gingerbread (1.01 ~ 3.07¾), 6-shogaol (0.64 ~ 1.09%). Regardless of the extraction temperature, the content of ginger was the lowest at 100 bar, and as the extraction temperature was increased, it decreased to 20.00, 18.02 and 15.13%, respectively. On the other hand, in the range of 200 ~ 400 bar, the content of ginger (gingerol) showed no difference as 21.46-24.48%.
【표 2] [Table 2]
초임계 추출 온도와 압력별 생강추출물의 진저를 함량 변화 Changes in Ginger Extract Content of Supercritical Extraction Temperature and Pressure
분석 결과는 다음과 같다. The analysis results are as follows.
【표 3】 Table 3
생강 에탄올추출물 및 분획물의 주요성분함량 분석 Analysis of Main Components of Ginger Ethanol Extract and Fraction
SFE marc: 실시예 2에 따른 생강박 추출물 SFE marc: Ginger foil extract according to Example 2
N.D.： not detected N.D .： not detected
표 3의 결과와 같이 핵산층에 진저를류의 함량이 가장 높았으며 , 6一 진저를이 24.97%로 주요 성분임을 알 수 있다. 또한， 생강박 추출물에는 진저를， 쇼가올류가 매우 낮게 검출되어 초임계 생강유로 효율적으로 추출된 것으로 보인다. 실험예 4: 생강 추출물의 항산화 활성 DPPH ( 2 , 2-d i heny 1 - 1- i c r y 1 -hydr azy 1 ) 라디칼 소거능 As shown in the results of Table 3, the content of ginger in the nucleic acid layer was the highest, and it can be seen that the six-component ginger is the main component of 24.97%. In addition, the ginger foil extract ginger, the shogaol is detected very low seems to be efficiently extracted with supercritical ginger oil. Experimental Example 4: Antioxidant Activity of Ginger Extract DPPH (2, 2-d i heny 1-1-i c r y 1 -hydr azy 1) Radical Scavenging Activity
추출물의 항산화력은 Moreno 등의 방법을 변형한 DPPH 라디칼 소거활성으로 측정하였다. 시료의 free radical 소거활성은 stable radical인 2,2(Hliphenylpicrylhydrazyl (DPPH)에 대한 환원력을 측정한 것으로 99% 메탄을에 각 시료를 녹여 농도 별로 희석한 희석액 800 tiL와 메탄을에 녹인 0.15 mM DPPH용액 200 L를 가하여 30분 방치한 후 517nm에서 흡광도를 측정하였다. 각 시료 추출물의 유리 라디칼 소거활성은
시료를 첨가하지 않은 대조구의 흡광도를 1/2로 환원 시키는데 필요한 시료의 농도인 RC50값으로 나타내었다. 이때 활성비교를 위하여 BHA를 사용하였다. ABTS 라디칼 소거능 The antioxidant activity of the extract was measured by DPPH radical scavenging activity modified from Moreno et al. Of sample f ree radical scavenging activity was 0.15 mM dissolved in the stable radical of 2, 2 (a diluted solution with 800 tiL diluted methane as a measure of the reducing power on Hliphenylpicrylhydrazyl (DPPH) is dissolved at different concentrations for each sample on a 99% methane DPPH After leaving for 30 minutes with 200 L of solution, the absorbance was measured at 517 nm. The absorbance of the control without the sample was expressed as RC50, which is the concentration of the sample required to reduce the absorbance to 1/2. At this time, BHA was used for activity comparison. ABTS radical scavenging activity
추출물의 ABTS 라디칼 소거능은 Re 등의 방법을 변형한 방법으로 즉정하였다. 2,2'-Azinobis 3一 ethyl benzothiazol ine-6-sul fonic acid(ABTS) radical을 이용한 항산화력 측정은 ABTS cation decolor izat ion assay 법에 의해 측정하였다. 7 mM ABTS와 2.45 mM potassium persulfate를 최종농도로 1:1로 흔합하여 실온인 암소에서 24시간 동안 방치하여 ABTS radical올 형성시키고 732 nm에서 흡광도 값이 0.7±0.02가 되도록 phsphate buffer salineCPBS, pH 7.4)로 희석하여 사용하였다. 희석된 시료 990 iiL에 ABTS radical 10 yL 를 넣고 1분 동안 방치한 후 732 誦에서 흡광도를 측정하였다. 각 시료 추출물의 유리 라디칼 소거활성은 시료를 첨가하지 않은 대조구의 흡광도를 1/2로 환원시키는데 필요한 시료의 농도인 RC50값으로 나타내었다. 이때 활성비교를 위하여 Trolox를 사용하였다. ABTS radical scavenging ability of the extract was immediately modified by a method such as Re. Antioxidant activity was measured by ABTS cation decolor izat ion assay using 2,2'-Azinobis 3 ethyl ethyl benzothiazol ine-6-sul fonic acid (ABTS) radical. 7 mM ABTS and 2.45 mM potassium persulfate were mixed at a final concentration of 1: 1 and left for 24 hours in a dark room at room temperature to form ABTS radicals, and the absorbance value was 0.7 ± 0.02 at 732 nm in phsphate buffer salineCPBS, pH 7.4). Dilute to and use. 10 yL of ABTS radical was added to 990 iiL of the diluted sample, and the absorbance was measured at 732 후. The free radical scavenging activity of each sample extract was expressed by the RC50 value, which is the concentration of the sample required to reduce the absorbance of the control group without the sample to 1/2. At this time, Trolox was used for activity comparison.
Linoieic acid와 β -carotene의 coupled oxidation에 대한 항산화 활성 Antioxidant Activity of Coupled Oxidation of Linoieic Acid and β-carotene
Linoieic acid 60 mg, β一 carotene 10 mg 그리고 Tween 80 200 mg과 chloroform 10 mL를 흔합하여 농축시킨 후 증류수 50 mL에 용해하여 용액으로 사용하였다. 흔합용액 1 mL와 증류수 2 mL, 그리고 생강 추출물 (20 mg/mL EtOH) 0.05 mL를 흔합한 후 40°C water bath에서 24시간 유지하면서 꺼내어 470 nm에서 흡광도를 측정하였다. 제조 직후의 흡광도 값을 100으로 하여 측정된 흡광도 값으로부터 항산화 활성을 산출하였다. 이때 생강 추출물 대신 증류수를 0.05 mL 처리한 것을 대조구로 하였다. 초임계 추출 온도와 압력별 생강추출물의 DPPH와 ABTS 라디칼 소거 활성을 측정한 결과는 하기 표 4에 나타낸 바와 같다. 초임계 추출물 (생강오일)은 에탄올 추출물과 비교하여 모든 초임계 추출조건에서 매우
낮은 RC50 값 (0·24~0.68)을 나타내어 강한 항산화 활성을 갖는 것으로 나타났다. 특히 45°C, 300 bar에서는 각각 RC50 값이 0.09， 0.55 yg/mL로 가장 높은 항산화 활성을 나타내었다. 또한， 생강 박 추출물의 DPPH와 ABTS 라디칼 소거 활성도 온도와 압력에 따른 항산화 활성의 경향은 뚜렷하지 않았으나, 55°C, 100 bar에서 각각 22.87， 20.17 yg/mL으로 가장 높은 활성을 나타냈다. 한편， Linoleic acid와 β -carotene의 coupled oxidation에 대한 항산화 활성을 측정한 결과는 도 3에 나타낸 바와 같다. 생강 추출물을 첨가하지 않은 대조구의 경우 2시간 경과시 71.1%의 항산화 활성을 갖는 것으로 나타나 짧은 시간에 급격히 산화가 일어남을 알 수 있었다. 생강 추출물을 첨가할 경우 처리구에 따라 차이가 있지만 84.499.3%의 활성을 나타내어 대조구에 비해 산화가 크게 억제됨을 알 수 있었다. 또한 24시간 경과시에도 대조구가 52. 의 항산화 활성을 나타내는 반면 생강 추출물 처리시에는 57.3~77.8%의 항산화 활성을 나타내는 것으로 나타났다. DPPH와 ABTS 라디칼 소거 활성과 마찬가지로 추출온도에 상관없이 100 bar에서 가장 낮은 항산화 활성올 나타내고 200-400 bar의 범위에서는 큰 차이가 나지 않는 항산화 활성을 갖는 것으로 나타났다. 이와 같은 항산화 활성 결과는 앞에서 기술한 추출물의 진저롤 함량의 경향과 거의 유사한 경향인 것으로 생강 추출물의 항산화 활성이 진저를 함량과 매우 큰 상관관계가 있음을 알 수 있었다. 60 mg of Linoieic acid, 10 mg of β-carotene, 200 mg of Tween 80, and 10 mL of chloroform were concentrated and dissolved in 50 mL of distilled water. After mixing 1 mL of the mixed solution, 2 mL of distilled water, and 0.05 mL of ginger extract (20 mg / mL EtOH), the absorbance was measured at 470 nm after being kept in a 40 ° C water bath for 24 hours. The antioxidant activity was computed from the absorbance value measured using the absorbance value just after manufacture as 100. In this case, 0.05 mL of distilled water instead of ginger extract was used as a control. The results of measuring DPPH and ABTS radical scavenging activity of ginger extracts by supercritical extraction temperature and pressure are shown in Table 4 below. Supercritical extract (ginger oil) is very effective under all supercritical extraction conditions compared to ethanol extract. Low RC50 values (0 · 24 ~ 0.68) showed strong antioxidant activity. Especially, at 50 ° C and 300 bar, RC50 values were 0.09 and 0.55 yg / mL, respectively. In addition, the DPPH and ABTS radical scavenging activity of ginger gourd extract was not obvious trend of antioxidant activity with temperature and pressure, but the highest activity was 22.87, 20.17 yg / mL at 55 ° C and 100 bar, respectively. On the other hand, the results of measuring the antioxidant activity of the coupled oxidation of linoleic acid and β-carotene are shown in FIG. The control group without the ginger extract had an antioxidant activity of 71.1% after 2 hours, indicating that oxidation occurred rapidly in a short time. The addition of ginger extract showed a difference depending on the treatment, but showed 84.499.3% of activity, indicating that oxidation was significantly inhibited compared to the control. In addition, the control group showed antioxidant activity of 52. even after 24 hours, while ginger extract treatment showed an antioxidant activity of 57.3 ~ 77.8%. Like DPPH and ABTS radical scavenging activity, it was shown to have the lowest antioxidant activity at 100 bar regardless of extraction temperature and to have an insignificant antioxidant activity in the range of 200-400 bar. The results of the antioxidant activity were almost similar to the tendency of the ginger roll content of the extract described above, and the antioxidant activity of the ginger extract was found to be highly correlated with the ginger content.
【표 4】 Table 4
생강 에탄을 추출물 및 초임계 추출물의 초임계 추출 온도와 압력별 항산화 활성 Antioxidant Activity of Supercritical Extraction Temperature and Pressure of Ginger Ethane Extracts and Supercritical Extracts
300bar 0.09±0.03 0.55±0.35300bar 0.09 ± 0.03 0.55 ± 0.35
400bar 0.19±0.03 0.53±0.45400bar 0.19 ± 0.03 0.53 ± 0.45
55 °C lOObar 0.68±0.03 0.62±0.05 55 ° C lOObar 0.68 ± 0.03 0.62 ± 0.05
200bar 0.18±0.01 0.41±0.07 200 bar 0.18 ± 0.01 0.41 ± 0.07
300bar 0.20±0.03 0.35±0.10300bar 0.20 ± 0.03 0.35 ± 0.10
400bar 0.14±0.02 0.35±0.09400bar 0.14 ± 0.02 0.35 ± 0.09
BHA 2.53±1.06 BHA 2.53 ± 1.06
Trolox 6.12±2.06 Trolox 6.12 ± 2.06
EtOH: 비교예에 따른 생강 에탄올 추출물 EtOH: ginger ethanol extract according to the comparative example
나머지 추출물: 실시예 1에 따른 생강 초임계 추출물 Remaining extract: Ginger supercritical extract according to Example 1
【표 5】 Table 5
생강 초임계 박 추출물의 항산화 활성 Antioxidant Activity of Ginger Supercritical Gourd Extract
(1) 실험방법 (1) Experimental method
1) 세포배양 및 세포 독성 측정 1) Cell culture and cytotoxicity measurement
대식세포 계열 (murine macrophage cell line)인 RAW 264.7 세포주를 한국 세포주 은행 (KCLB, Seoul, Korea)으로부터 분양받았으며， 10¾> FBS(fetal bovine serum)와 1% 항생제 (penici 11 in/streptomycin)를 첨가한 DMEM 배지를 이용하여 5% C02가 존재하는 37°C 인큐베이터에서 1주일에 2~3회 계대 배양하였다. RAW 264.7 cell line (murine macrophage cell line) was distributed from Korea Cell Line Bank (KCLB, Seoul, Korea) and added 10¾> FBS (fetal bovine serum) and 1% antibiotic (penici 11 in / streptomycin). DMEM medium was passaged 2-3 times a week in a 37 ° C incubator in the presence of 5% C0 2 .
세포 독성을 MTT 법으로 측정하기 위하여， R 264.7 세포 lx 105 cells/well을 96 well plate에 분주하고， 37°C , 5% C02 인큐베이터에서 24시간 동안 배양하였다. 배양한 세포를 세럼 프리 (serum free) 배지로 교체한 후 LPS (100 ng/mL)와 시료 (실시예 1, 실시예 2， 비교예)를 각각 처리하여 24시간 배양하여 5 mg/mL의 ΜΊΤ 용액 10 yL를 각 well에 넣고 인큐베이터에서 4시간 동안 배양하였다. 배양 종료 후 상등액을 제거하고 각 well에 100 의 DMS0를 첨가하여 생성된 formazan 결정을 용해시켜 마이크로플레이트 판독기 (microplate reader)로 550 nm에서 흡광도를 측정하였고, 세포독성은 시료의 흡광도를 대조군의 흡광도에 대한 백분율로 나타내었다. In order to measure cytotoxicity by MTT method, R 264.7 cells lx 10 5 cells / well were dispensed into 96 well plates and incubated for 24 hours in a 37 ° C, 5% C0 2 incubator. The cultured cells were replaced with a serum free medium, and then treated with LPS (100 ng / mL) and samples (Examples 1, 2, and Comparative Example) for 24 hours, followed by 5 mg / mL ΜΊΤ. 10 yL of the solution was added to each well and incubated for 4 hours in an incubator. After the incubation period, the supernatant was removed, and formazan crystals were dissolved by adding 100 DMS0 to each well, and the absorbance was measured at 550 nm using a microplate reader. Cytotoxicity was determined by absorbance of the sample to the absorbance of the control group. Expressed as a percentage.
Rat 유래의 비만세포주 (RBL-2H3)에 대한 세포독성능도 MTT 법으로 실험하였다. 본 실험에 사용한 세포주 RBL-2H3 cell은 한국 세포주 은행 (Seoul, Korea)을 통해서 분양 받아 계대배양하면서 실험하였다. 세포배양에 사용된 배지는 10% FBS (fetal bovine serum)와 1% 항생제 (penicillin/streptomycin)를 첨가한 MEM 배지를 이용하여 37°C에서
5% C02인큐베이터에서 2~3일간 배양한 후 사용하였다. 2) NOCNitric Oxide) 생성량 측정 Cytotoxic activity against rat-derived mast cell line (RBL-2H3) was also tested by MTT method. The cell line RBL-2H3 cells used in this experiment were tested by subculture by receiving them through the Korea Cell Line Bank (Seoul, Korea). The medium used for cell culture was 37 ° C. using MEM medium containing 10% FBS (fetal bovine serum) and 1% antibiotic (penicillin / streptomycin). It was used after incubating for 2-3 days in a 5% CO 2 incubator. 2) NOCNitric Oxide)
시료의 NCKNitric Oxide) 생성 억제능을 측정하기 위하여, 각 시료 (실시예 1, 실시예 2， 비교예)의 추출물 혹은 LPS를 처리한 상기 RAW 264.7 세포주 배양액을 nitrite 측정을 위해 100 를 96 well plate에 취하였다. 여기에 동량의 Griess 시약을 넣어 10분간 반웅시킨 후 마이크로플레이트 판독기 (microplate reader)를 이용하여 540 nm에서 흡광도를 측정하였다. Nitrite의 농도는 질산나트륨 (NaN02)을 사용하여 얻은 표준 직선과 비교하여 산출하였다. In order to measure the inhibitory ability of NCKNitric Oxide production of the sample, extract of each sample (Example 1, Example 2, Comparative Example) or the LPS-treated RAW 264.7 cell line culture medium were taken in a 96 well plate for 100 nitrite measurement. It was. An equal amount of Griess reagent was added thereto and reacted for 10 minutes, and then absorbance was measured at 540 nm using a microplate reader. The concentration of nitrite was calculated by comparison with a standard straight line obtained using sodium nitrate (NaN0 2 ).
또한， 비만세포주 RBL-2H3을 1 ml(2 x 105 cells, 24 well plate)에 anti -DNP IgE(0.45 /zg/ml)로 16시간 감작시키고, DNP— BSA(10 /mL)로 활성화시키기 전에 30분 동안 37°C에서 농도별 시료를 20 ml 처리하였다. 반응이 끝난 후 4°C에서 10분간 400 xg에서 원침하여 얻은 상등액 25 ^를 기질 pᅳ nitropheny卜 N-acetyl-b-D-glucosaminide 25 와 37°C에서 1시간 반웅시킨 후 stop solution(0.1 M NaCO/NaHCO, H 10) 200 ≠를 가하여 정지시키고 405 nm에서 흡광도를 측정하여 b_핵소사미니다제 (b- hexosaminidase)의 양을 계산하였다. 3) Heme oxygenase (H0)-1의 발현량 측정 In addition, the mast cell line RBL-2H3 was sensitized in 1 ml (2 x 10 5 cells, 24 well plates) with anti -DNP IgE (0.45 / zg / ml) for 16 hours and activated with DNP—BSA (10 / mL). 20 ml of the concentration-specific sample was treated at 37 ° C for 30 minutes before. After the reaction, the supernatant 25 ^ obtained by centrifugation at 400 xg for 10 minutes at 4 ° C was reacted with substrate p ᅳ nitropheny® N-acetyl-bD-glucosaminide 25 and 37 ° C for 1 hour, and then stop solution (0.1 M NaCO / NaHCO, H 10) 200 ≠ was added to stop and absorbance at 405 nm to calculate the amount of b_ hexosaminidase (b- hexosaminidase). 3) Determination of the expression level of heme oxygenase (H0) -1
생강 박 추출물의 항염증성 단백질인 heme oxygenase (H0)-1의 발현에 대한 효과를 알아보기 위하예 시료를 농도별로 전 처리 한 RAW 264.7 cell에 LPS로 염증을 유도하여 항염증 효과가 H0-1의 발현에 의한 것인지 알아보았다. H0-1항체를 이용하여 western blot 방법으로 분석하였다. To investigate the effect of Ginger gourd extract on the expression of anti-inflammatory protein heme oxygenase (H0) -1, LPS was induced in RAW 264.7 cells pretreated with different concentrations. It was examined whether it is by expression. Western blot analysis was performed using H0-1 antibody.
4) 베타-핵소사미니다제 (beta-hexosaminidase)의 방출량 측정 초임계 박을 사용하여 항 알러지 비만세포주 RBL-2H3을 1 ml (2 x lOcells, 24 well plate)에 anti -DNP IgE(0.45 //g/ml)로 16시간 감작시키고 DNP-BSAC10 ag/mL)로 활성화시키기 전에 30분 동안 37°C에서 농도별 시료를 20 ml 처리하여 반응이 끝난 후 4°C에서 10분간 400°C에서 원침하여 얻은 상등액 25 를 기질 p-ni t ropheny 1 -N-acety 1 -b -D-glucosaminide 25 와
37°C에서 1시간 반응시킨 후 stop solution(0.1 M NaCO/NaHCO, pH 10) 200 βί를 가하여 정지시키고 405 nm에서 흡광도를 측정하여 베타- 핵소사미니다제 (beta-hexosaminidase)의 양을 계산하였다. (2) 실험 결과 4) Determination of the release of beta-hexosaminidase Anti-DNP IgE (0.45 // in anti-allergic mast cell line RBL-2H3 in 1 ml (2 x lOcells, 24 well plates) using supercritical gourd. 16 hours primed with g / ml) and centrifuged in DNP-BSAC10 ag / mL) activation to 30 minutes 4 ° C for 10 minutes at 400 ° C after the reaction was completed by 20 ml handle concentrations sample at 37 ° C over prior to The supernatant 25 obtained by using the substrate p-ni t ropheny 1 -N-acety 1 -b -D-glucosaminide 25 After reacting at 37 ° C. for 1 hour, 200 βί was stopped by adding stop solution (0.1 M NaCO / NaHCO, pH 10), and the absorbance was measured at 405 nm to calculate the amount of beta-hexosaminidase. . (2) experimental results
1) 초임계 추출물 (생강유)의 세포독성 및 N0 생성 억제 활성 측정 생강의 초임계 추출물 (생강유)의 항염증 효과를 측정하기 위해, 100 bar의 압력에서 35, 45， 55°C에서 추출된 생강유 (실시예 1)의 N0 소거 활성을 측정하였다. 그 결과, 55 °C의 100 μg/mL 농도에서 약간의 독성이 나타났으며， 추출온도가 높아지면 N0 생성 억제능이 낮아지는 경향을 나타내어 고온에서는 활성을 억제하는 성분도 유출되는 것으로 사료되나， 온도에 의한 유의적인 차는 없었다 (도 4). 이와 같이 , 35-55°C , 100 bar의 마일드한 조건에서 추출된 생강 초임계 오일에서도 높은 N0 소거능이 나타났다, 1) Determination of Cytotoxicity and N0 Production Inhibitory Activity of Supercritical Extracts (Ginger Oil) To determine the anti-inflammatory effects of supercritical extracts (ginger oil) of ginger, extracted at 35, 45, 55 ° C at a pressure of 100 bar NO scavenging activity of the ginger oil (Example 1) was measured. As a result, a slight toxicity was observed at 100 μg / mL concentration at 55 ° C. When the extraction temperature was increased, the N0 inhibitory activity tended to be lowered. There was no significant difference by (FIG. 4). As such, high N0 scavenging activity was observed even in ginger supercritical oil extracted under mild conditions of 35-55 ° C and 100 bar.
2) 초임계 박의 세포독성 측정 및 N0 생성 억제 활성 측정 2) Measurement of cytotoxicity and N0 production inhibitory activity of supercritical gourd
실시예 2의 생강 추출물의 N0 생성에 대한 억제 효과를 실험하였다. 그 결과， 도 5에 나타낸 바와 같이 추출 온도에 비례하여 고농도에서 세포 독성이 나타났으며， N0 소거능도 온도 상승과 함께 증가하는 경향을 나타내어 실시예 1의 생강 추출물와 일치하는 좋은 상관관계를 나타냈다. 10-50 /g/mL의 농도 구간에서 농도 의존적으로 높은 억제율을 나타내므로， 실시예 1의 생강 추출물과 함께 실시예 2의 초임계 박도 항염증에 높은 효과가 있을 것으로 기대된다. The inhibitory effect on NO production of the ginger extract of Example 2 was examined. As a result, as shown in FIG. 5, cytotoxicity was observed at high concentrations in proportion to the extraction temperature, and the N0 scavenging activity also showed a tendency to increase with an increase in temperature, indicating a good correlation with the ginger extract of Example 1. Since the concentration-dependent high inhibition rate in the concentration range of 10-50 / g / mL, together with the ginger extract of Example 1 is expected to have a high effect on the super-critical thin anti-inflammatory.
3) 생강 추출물의 세포독성 및 N0 생성 억제능 측정 3) Measurement of Cytotoxicity and N0 Production Inhibitory Activity of Ginger Extract
비교예의 생강 추출물의 N0 생성에 대한 억제 효과를 실험하였다. 그 결과， 도 6에 나타낸 바와 같이 세포 독성은 나타나지 않았으며, N0 소거능은 농도 의존적으로 함께 증가하는 경향을 나타내었다 (도 6). The inhibitory effect on NO production of the ginger extract of the comparative example was examined. As a result, as shown in FIG. 6, no cytotoxicity was observed, and N0 scavenging ability was increased in a concentration-dependent manner (FIG. 6).
4) 진저를 (Gingerol)의 세포독성 측정 및 N0 생성 억제 활성 측정
생강의 활성 성분으로 알려진 진저롤 (gingerol)의 NO 생성에 대한 억제 효과를 테스트 한 결과， 100 /g/mL 까지는 세포 독성이 없었으며 10 /g/mL에서 50% 정도의 NO 억제능을 나타냈다 (도 7). 5) Heme oxygenase(HO)-l의 발현량 측정 4) Determination of Gingerol Cytotoxicity and N0 Production Inhibitory Activity Testing the inhibitory effect of ginger on NO production, known as the active ingredient of ginger, showed no cytotoxicity up to 100 / g / mL and showed about 50% NO inhibition at 10 / g / mL (Fig. 7). ). 5) Determination of the expression level of heme oxygenase (HO) -l
항염증성 단백질인 heme oxygenase (HO) -1의 발현량을 측정한 결과， 도 8에서 보여지듯이 생강박 추출물은 낮은 농도 구간에서도 항산화， 항알러지 단백질로 알려진 H0-1을 농도 의존적으로 발현시키는'것을 알 수 있다. As shown in an anti-inflammatory protein, heme oxygenase (HO) As a result of measuring the expression level of 1, 8 that "foil of ginger extract expressing H0-1 known as antioxidants, anti-allergy protein even at a low concentration region in a concentration-dependent manner Able to know.
6) 베타-핵소사미니다제 (beta-hexosaminidase)의 방출량 측정 알러지 반응을 일으키는 비만세포 탈과립의 마커 효소인 beta- hexosaminidase의 방출량을 측정한 결과， 도 9a, 9b와 같이, 생강 초임계 추출물과 생강박 추출물의 비만세포 활성 억제 효과를 에탄올 추출물 활성과 비교하면 생강 초임계 추출물， 특히 생강박 추출물에서 농도 의존적으로 비만세포 탈과립의 마커 효소인 beta-hexosaminidase의 방출을 유의적으로 억제하는 것을 알수 있다. 6) Measurement of the release amount of beta-hexosaminidase (beta-hexosaminidase) As a result of measuring the release amount of beta-hexosaminidase, a marker enzyme of mast cell degranulation causing an allergic reaction, as shown in Figure 9a, 9b, ginger supercritical extract and ginger Compared to the ethanol extract activity, the inhibitory effect of gourd extract was significantly inhibited by the release of beta-hexosaminidase, a marker enzyme of mast cell degranulation, in a concentration-dependent manner.
【산업상 이용가능성】 Industrial Applicability
이상 살펴본 바와 같이 본 발명은 생강을 특정 조건으로 초임계 추출함으로써 생강 특유의 맛과 향기를 제거하거나 보완할 수 있을 뿐 아니라 짧은 시간 안에 추출 수율을 높으면서도 진저를 (gingerol)의 함량이 높은 추출물을 얻을 수 있어 식품산업에 매우 유용한 발명이다. As described above, the present invention not only removes or supplements ginger's unique taste and aroma by supercritical extraction under specific conditions, but also has a high content of ginger while extracting extracts in a short time. It is a very useful invention for the food industry.
또한, 본 발명은 상기 초임계 추출 후 남은 생강박을 활용하여 항염 및 항알러지 활성이 높은 생강 추출물을 얻을 수 있다. 이상에서 본 발명의 바람직한 실시예에 대하여 도시하고 또한 설명하였으나， 본 발명은 상기한 실시예에 한정되지 않고， 이하 청구범위에서 청구 는 본 발명의 요지를 벗어남이 없이 당해 발명의 분야에서 통상의 지식을 가진 자라면 누구든지 다양한 변형실시가 가능함은 물론이며， 그와 같은 변형은 청구범위의 기재 범위 내에 있게 된다.
In addition, the present invention can obtain a high anti-inflammatory and anti-allergic ginger extract by utilizing the remaining ginger foil after the supercritical extraction. Although preferred embodiments of the present invention have been illustrated and described above, the present invention is not limited to the above-described embodiments, and the claims in the following claims are common knowledge in the field of the present invention without departing from the gist of the present invention. Anyone with a variety of modifications are possible, of course, such modifications are within the scope of the claims.
Claims
【청구의 범위】 [Range of request]
【청구항 1】 [Claim 1]
(S1) 생강 분말을 준비하는 단계 ; 및 (S1) preparing a ginger powder; And
(S2) 생강 분말을 초임계 이산화탄소를 이용하여 35 ~ 55°C의 온도,(S2) Ginger powder temperature of 35-55 ° C, using supercritical carbon dioxide
100 ~ 400 bar의 압력에서 1 ~ 3 mL/min의 유속으로 1 ~ 3 시간 동안 초임계 추출법으로 추출하여 생강유를 얻는 단계;를 포함하는 생강 추출물 제조방법. 【청구항 2】 Ginger extract manufacturing method comprising; extracting ginger oil by supercritical extraction for 1 to 3 hours at a flow rate of 1 to 3 mL / min at a pressure of 100 ~ 400 bar. [Claim 2]
제 1항에 있어서， The method of claim 1,
(S1) 단계에서의 생강 분말은 평균 입도가 50 ~ 500 μηι인 생강 추출물 제조방법 . 【청구항 3】 Ginger powder in the step (S1) is a ginger extract manufacturing method having an average particle size of 50 ~ 500 μηι. [Claim 3]
게 1항에 있어서， According to claim 1,
추출 수율이 2.5 - 3.0중량¾)인 생강 추출물 제조방법 . 【청구항 4] Ginger extract manufacturing method with an extraction yield of 2.5-3.0 weight ¾). [Claim 4]
제 1항에 있어서, (S2) 단계 이후에 The method of claim 1, wherein after step (S2)
(53) 생강유를 얻은 후 남은 박을 생강 박 무게에 대하여 5 ~ 15배 (w/v)의 60 ~ 90% 주정을 가하고 실온에서 6 ~ 36시간 동안 정치하는 단계 ; 및 (53) adding the remaining watermelon after obtaining ginger oil, 5 to 15 times (w / v) of 60 to 90% alcohol relative to the weight of ginger foil and left to stand for 6 to 36 hours at room temperature; And
(54) 여과 및 농축하는 단계;를 더 포함하는 생강 추출물 제조방법. (54) filtration and concentration; ginger extract manufacturing method further comprising.
【청구항 5】 [Claim 5]
거 U항 내지 제 4항 중 어느 한 항의 방법에 따라 제조된 생강 추출물. Ginger extract prepared according to the method of any one of claims U to 4.
【청구항 6】 [Claim 6]
게 5항에 있어서， According to claim 5,
진저를 (gingerol)의 함량이 21 ~ 25중량 %인 생강 추출물.
【청구항 7] Ginger extract with a ginger content of 21 to 25% by weight. [Claim 7]
거 15항에 있어서， According to claim 15,
10 - 100 g/mL의 농도에서 NCKNitric Oxide) 생성 억제 효과가 50 -8%인 생강 추출물. Ginger extract with 50 -8% inhibitory effect on NCKNitric Oxide production at a concentration of 10-100 g / mL.
【청구항 8】 [Claim 8]
제 5항의 생강 추출물을 포함하는 항염증 조성물. 【청구항 9] Anti-inflammatory composition comprising a ginger extract of claim 5. [Claim 9]
제 5항의 생강 추출물을 포함하는 항알러지 조성.물.
An anti-allergic composition comprising the ginger extract of claim 5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2011-0008991 | 2011-01-28 | ||
| KR1020110008991A KR101324926B1 (en) | 2011-01-28 | 2011-01-28 | Manufacturing Mathod of Ginger Extract And Ginger Extract Using The Same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012102511A2 true WO2012102511A2 (en) | 2012-08-02 |
| WO2012102511A3 WO2012102511A3 (en) | 2012-11-29 |
Family
ID=46581254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2012/000437 WO2012102511A2 (en) | 2011-01-28 | 2012-01-18 | Ginger extract production method and ginger extract obtained thereby |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101324926B1 (en) |
| WO (1) | WO2012102511A2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105495520A (en) * | 2015-11-26 | 2016-04-20 | 怀化学院 | Instant fresh-ginger powder and preparation method of the instant fresh-ginger powder |
| CN107118842A (en) * | 2016-02-25 | 2017-09-01 | 山东省康福德实业有限公司 | A kind of oil of ginger extraction process flow of utilization supercritical extraction technique |
| CN107460032A (en) * | 2017-09-18 | 2017-12-12 | 广西大学 | A kind of method for extracting effective components of ginger |
| US10159268B2 (en) | 2013-02-08 | 2018-12-25 | General Mills, Inc. | Reduced sodium food products |
| CN113925948A (en) * | 2020-07-14 | 2022-01-14 | 香港大学 | Application of ginger total extract or active ingredients thereof, pharmaceutical composition and preparation method |
| CN115721768A (en) * | 2022-12-01 | 2023-03-03 | 国纳之星(上海)纳米科技发展有限公司 | Preparation method of anti-inflammatory silk fibroin film, product and application thereof |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102972755A (en) * | 2012-11-14 | 2013-03-20 | 汾州裕源土特产品有限公司 | Walnut oil soft capsule and preparing method thereof |
| KR101582197B1 (en) * | 2013-12-11 | 2016-01-21 | 한국식품연구원 | Preparation method of ginger with increased shogaol content |
| KR101868225B1 (en) * | 2016-09-22 | 2018-06-15 | 주식회사 담터 | A method of extracting shogaol from ginger |
| KR102063444B1 (en) | 2018-08-20 | 2020-01-08 | 이종관 | Manufacturing method of ginger powder with mild flavor |
| KR102435400B1 (en) * | 2020-06-08 | 2022-08-24 | 광동제약 주식회사 | Steamed ginger extract with increased 6-gingerol contents and a method of preparation thereof |
| KR20230044772A (en) | 2021-09-27 | 2023-04-04 | (주) 대진에프아이 | Complex processing method of ginger for producing oligosaccharide |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002047195A (en) * | 2000-07-12 | 2002-02-12 | Pharmaceutical Industry Technology & Development Center | Method for producing extract containing active ingredient of ginger and pharmaceutical composition comprising the same extract |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100214801B1 (en) * | 1996-10-05 | 1999-08-02 | 신국현 | Antibiotics isolated from lindera obstiloba |
| PL205881B1 (en) | 2001-11-26 | 2010-06-30 | Finzelberg Gmbh & Co Kg | Ginger extract preparation |
| KR100623003B1 (en) | 2004-12-22 | 2006-09-14 | 전북대학교산학협력단 | Manufacturing Method of Ginger Extract using Ultrasonication |
-
2011
- 2011-01-28 KR KR1020110008991A patent/KR101324926B1/en active IP Right Grant
-
2012
- 2012-01-18 WO PCT/KR2012/000437 patent/WO2012102511A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002047195A (en) * | 2000-07-12 | 2002-02-12 | Pharmaceutical Industry Technology & Development Center | Method for producing extract containing active ingredient of ginger and pharmaceutical composition comprising the same extract |
Non-Patent Citations (3)
| Title |
|---|
| AHN, JEONG TAEK ET AL.: 'The Korean Society of Food Science and Nutrition' INTERNATIONAL SYMPOSIUM AND ANNUAL MEETING 27 October 2010, page 269 * |
| KWON, KI WON ET AL. KOREAN JOURNAL OF ORIENTAL MEDICAL PATHOLOGY vol. 22, no. 3, 25 June 2008, pages 585 - 592 * |
| LIM, KANG MIN ET AL. KOREAN JOURNAL OF ORIENTAL MEDICAL PATHOLOGY vol. 20, no. 6, 25 December 2006, pages 1467 - 1476 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10159268B2 (en) | 2013-02-08 | 2018-12-25 | General Mills, Inc. | Reduced sodium food products |
| US11540539B2 (en) | 2013-02-08 | 2023-01-03 | General Mills, Inc. | Reduced sodium food products |
| CN105495520A (en) * | 2015-11-26 | 2016-04-20 | 怀化学院 | Instant fresh-ginger powder and preparation method of the instant fresh-ginger powder |
| CN107118842A (en) * | 2016-02-25 | 2017-09-01 | 山东省康福德实业有限公司 | A kind of oil of ginger extraction process flow of utilization supercritical extraction technique |
| CN107460032A (en) * | 2017-09-18 | 2017-12-12 | 广西大学 | A kind of method for extracting effective components of ginger |
| CN113925948A (en) * | 2020-07-14 | 2022-01-14 | 香港大学 | Application of ginger total extract or active ingredients thereof, pharmaceutical composition and preparation method |
| CN113925948B (en) * | 2020-07-14 | 2023-10-10 | 香港大学 | Use of rhizoma Zingiberis recens total extract or its active component, pharmaceutical composition and preparation method |
| CN115721768A (en) * | 2022-12-01 | 2023-03-03 | 国纳之星(上海)纳米科技发展有限公司 | Preparation method of anti-inflammatory silk fibroin film, product and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120087652A (en) | 2012-08-07 |
| WO2012102511A3 (en) | 2012-11-29 |
| KR101324926B1 (en) | 2013-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012102511A2 (en) | Ginger extract production method and ginger extract obtained thereby | |
| Wu et al. | Supercritical carbon dioxide extract exhibits enhanced antioxidant and anti-inflammatory activities of Physalis peruviana | |
| Zhang et al. | Insights into the importance of dietary chrysanthemum flower (Chrysanthemum morifolium cv. Hangju)-wolfberry (Lycium barbarum fruit) combination in antioxidant and anti-inflammatory properties | |
| JP6666837B2 (en) | NOx inhibitors and NFκB inhibitors containing methoxyflavone | |
| US7811997B2 (en) | Composition containing total triterpenoid sapogenins extracted from bamboo, and the preparation method and use thereof | |
| KR102047222B1 (en) | Composition comprising extract of chrysanthemum as an effective ingredient for preventing or treating of muscular disorder or improvement of muscular functions | |
| JP6521949B2 (en) | Black ginger oil extract and method for producing the same | |
| EP2240193B1 (en) | Composition comprising the extracts of lindera obtusiloba for prevention and treatment of cardiovascular diseases | |
| Tisnadjaja et al. | Potency of cinnamomum burmannii as antioxidant and α glucosidase inhibitor and their relation to trans-cinamaldehyde and coumarin contents | |
| KR101541520B1 (en) | A method for preparation of extract mixture having antioxidant and antiaging activity from dendropanax morbifera, cornus fruit and lycium chinense, and cosmetic composition containing the extract | |
| US20120164132A1 (en) | Anticancer and immunomodulating molecules and fractions containing said molecules, and process for preparing said fractions and said molecules from fermented vegetal material, and their uses | |
| KR101793208B1 (en) | A compostion comprising Cotoneaster horizontalis Decne extract having anti-oxidation or anti-inflammation activity | |
| KR101236233B1 (en) | Pharmaceutical compositions and health functional foods compositions for the improvement of liver functions containing the extract of Youngia denticulata, fraction of thereof or compound isolated therefrom as an active ingredient | |
| KR20170002846A (en) | Composition containing extract of soybean leaves for suppressing and preventing myopathy | |
| KR20170055758A (en) | Anti inflammatory comprising plant extract | |
| KR20140084928A (en) | Composition for treating diabete and diabete-induced complication containing an extract from Agrimonia pilosa | |
| KR102044228B1 (en) | Isolating Method for Compounds having Antioxidant Ability from Adults of Tenebrio molitor | |
| EP2089505A1 (en) | Reduced-hangover alcoholic beverage | |
| KR102058022B1 (en) | Composition for antioxidant and anti-inflammatory comprising fraction of Ledum palustre L. extract as effective component | |
| JP6061482B2 (en) | Angiotensin II type 1 receptor antagonist and antihypertensive agent | |
| KR102154092B1 (en) | A compostion comprising Torreya nucifera seed extract or its fraction having anti-oxidation or anti-inflammation activity | |
| KR101768280B1 (en) | A composition comprising Carpinus pubescens extracts having anti-oxidation or anti-inflammation activity | |
| KR20140145666A (en) | Composition comprising natural complex of fucoxanthin, salix babylonica and low molecular weight alginate for preventing or treating of obesity | |
| CN112891352B (en) | Fermented product of lotus leaf and hawthorn extract and application of active ingredients of fermented product in inhibiting lipogenesis | |
| KR102182919B1 (en) | Composition for anti-aging or anti-wrinkle containing Uncarina stellulifera extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12739746 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12739746 Country of ref document: EP Kind code of ref document: A2 |